Retrospective study of cholecalciferol and calcitriol supplementation in Catalonia showing a small but significant lower risk of cases with cholecalciferol, but no significant difference for mortality, or for calcitriol supplementation. Significant benefit was found for cases, severity, and mortality in patients achieving serum vitamin D levels ≥30ng/ml.
risk of death, 1.0% higher, RR 1.01, p = 0.91, calcifediol, univariate.
|
risk of death, 4.0% lower, RR 0.96, p = 0.37, cholecalciferol, univariate.
|
risk of case, 1.0% lower, RR 0.99, p = 0.65, NNT 3499, calcifediol, univariate.
|
risk of case, 5.0% lower, RR 0.95, p = 0.004, cholecalciferol, multivariate.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Oristrell et al., 17 Jul 2021, retrospective, population-based cohort, Spain, peer-reviewed, 8 authors, dosage varies (calcifediol).